Device Trial Radar · NCT06854328
The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents
Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Jun 11, 2025
Primary completion
Aug 1, 2026
Study completion Nov 1, 2026
Sponsor
- Lead sponsor
- GrayMatters Health Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 3, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 12 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prism is a software as a medical device (SaMD) to be prescribed by clinicians as an adjunct to the standard of care treatment of patients with PTSD. The Prism software device runs on a laptop using an EEG signal input (g).Nautilos PRO (K171669). The primary objective of the study is to extend the use of the FDA cleared Prism for PTSD (K222101) to an adolescent population and to confirm the safety of fifteen (15±3) EEG-NF training sessions using the Prism software in reducing PTSD-related symptoms in adolescents. The study aims to demonstrate the safety profile of Prism, having no device-related serious adverse events (SAEs), consistent with findings in the adult population, throughout the course of Prism treatment in an adolescent population.
Conditions
- Post-Traumatic Stress Disorder in Adolescence
Interventions
PrismDevice
Prism is using an amygdala-fMRI-guided model for processing EEG signals. The model, termed EEG fMRI pattern (EFP), uses several electrodes EEG-signal to produce a real time amygdala-EFP biomarker signal. GrayMatters' product, Prism, is used to train patients in downregulating the amygdala-derived-EFP biomarker during therapy sessions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety reportingTime frame: 1 month
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
NYU Langone Health
New York, New York · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.